Anti-infective strategies in neutropenic patients

Acta Clinica Belgica

Volumn 53, Issue 3, 1998, Pages 168-177

  Maertens, J ^a   Boogaerts, M A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CILASTATIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GROWTH FACTOR; VANCOMYCIN;

ANTIBIOTIC THERAPY; BONE MARROW SUPPRESSION; CANCER PATIENT; GRAM NEGATIVE BACTERIUM; GRANULOCYTE TRANSFUSION; HUMAN; INFECTION CONTROL; NEUTROPENIA; PATIENT CARE; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0031871130     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754159     Document Type: Review

References (58)

1. Glauser M, Boogaerts M, Cordonnier C, Palmblad J, Martino P. Empirical therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect. 1997; 3 (suppl I): S77-S86.
2. Bodey GP, Bickley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med. 1966; 64: 328-40.
3. Walsh TJ, Hiemenz J, Pizzo PA. Editorial response: evolving risk factors for invasive fungal infections - All neutropenic patients are not the same. Clin Infect Dis. 1994; 18: 793-8.
4. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer. 1995; 31A: 2013-22.
5. Boogaerts MA. Anti-infective strategies in neutropenia. J Antimicrob Chemother. 1995; 36: 167-78.
6. Boogaerts MA. Problems of infection treatment in immunocompromised patients. Research and Clinical Forums. 1988; 10: 9-18.
7. Weinberger M, Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am. 1993; 7: 865-85.
8. Donnelly JP, De Pauw BE. Current infectious complications and their management in acute leukemia and bone marrow transplantation. Int J Antimicrob Agents. 1994; 3: 245-50.
9. Ochs L, Shu XO, Miller J, Enright H, Wagner J et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995; 86: 3979-86.
10. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-centre validation of a prediction rule. J Clin Oncol. 1992; 10: 316-22.
11. Talcott JA. Outpatient management of febrile neutropenia: should we change the standard of care? The Oncologist. 1997; 2: 365-73.
12. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy, in febrile neutropenic patients. Arch Intern Med. 1992; 152: 283-91.
13. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus irnipenern. J Clin Oncol. 1995; 13: 165-76.
14. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R et al. Monotherapy with meropenern versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996; 40: 1108-15.
15. Cometta A, Zinner SH, de Bock R, Calandra T, Gaya H et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995; 39: 445-52.
16. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med. 1994; 120: 834-44.
17. The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother. 1995; 36: 185-200.
18. Cordonnier C, Herbrecht R, Pico JL et al. Cefepimeamikacin versus ceftazidime-amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis. 1997; 24: 41-51.
19. Spencer RC, Bauernfeind A, Garcia-Rodriguez J, Jarlier V, Pfaller M et al. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin Microbiol Infect. 1997; 3: S21-S35.
20. Gordts B, Van Landuyt H, Ieven M, Vandamme P, Gooossens H. Vancomycin-resistant enterococci colonizing the intestinal tract of hospitalized patients. J Clin Microbiol. 1995; 33: 2842-6.
21. De Pauw BE, Meis JFGM. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer. 1998; 6: 31-8.
22. Reusser P. Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients. Support Care Cancer. 1998; 6: 39-45.
23. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropema. N Engl J Med. 1993; 328: 1323-32.
24. Richard P, Den Valle GA, Moreau P et al. Viridans streptococcal bacteremia in patients with neutropenia. Lancet. 1995; 345: 1607-9.
25. Klugman K, Goldstein F, Kohno S, Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 1997; 3: S48-S60.
26. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996; 9: 499-511.
27. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med. 1991; 324: 1005-11.
28. Flunn PM, van Hooser B, Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J. 1988; 7: 510-13.
29. Link H, Maschmeyer G, Meyer P et al. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol. 1994; 69: 231-43.
30. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis. 1990; 161: 397-401.
31. Feusner J, Cohen R, O'Leary M, Beach B. Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol. 1988; 11: 1699-702.
32. De Pauw BE, Dompeling EC. Antibiotic strategy after the empiric phase in patients treated for a hematological malignancy. Ann Hematol. 1996; 72: 273-9.
33. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis, 1995; 96(suppl): 34-7.
34. Ramphal R, Kramer BS, Rand KH, Weiner RS, Shands JW. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin, and gentamycin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother. 1983; 12(Suppl. A): 81-8.
35. Kramer BS, Ramphal R, Rand KH. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamycin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986; 30: 64-8.
36. Rubin M, Hathorn JW, Marshall J et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988; 108: 30-35.
37. Dompeling EC, Donnelly JP, Raemackers JMM, De Pauw BE. Preemptive administration of corticosteroids prevents the development of ARDS associated with Streptococcus mitis bacteremia following chemotherapy with high-dose cytarabine. Ann Hernatol. 1994; 69: 69-72.
38. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hospit Epidem. 1995: 16: 105-13.
39. EORTC and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients. J Infect Dis. 1991; 163: 951-8.
40. Novàkovà IRO, Donnelly JP, De Pauw BE. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1991; 35: 672-8.
41. Ramphal R, Bolger M, Oblon W et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother. 1992; 36: 1062-7.
42. Dompeling EC, Donnelly JP, Deresinski SC et al. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer. 1996; 34A: 1332-9.
43. Maschmeyer G, Hiddemann W, Link H et al. Management of infections during intensive treatment of hematologic malignancies. Ann Hematol. 1997; 75: 9-16.
44. Huahes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997; 25: 551-73.
45. Neldhart J, Mangalik A, Kohler W et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone-marrow-transplantation. J Clin Oncol. 1989; 7: 1685-92.
46. Herbrecht R, Cordonnier C. Impact of cytokines and growth factors in the antifungal armamentarium. In: Baillière's Clinical Infectious Diseases. 1995; 2: 141-55.
47. Biesma B, de Vries EGE, Willemse PHB et al. Efficacy and tolerability of recombinant human granulocyte-marcophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer; 1990; 26: 932-6.
48. Maher DW, Lieschke JL, Green M et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med. 1994; 121: 492-501.
49. Riikonen P, Saarinen UM, Mäkipernaa A et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J. 1994; 13: 197-202.
50. Mayordomo JI, Rivera F, Diaz-Puente MT et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995; 87: 803-8.
51. Vellenga E, Uyl-de Groot CA. de Wit R et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol. 1996; 14: 619-27.
52. Anaissie EJ, Vartivarian S, Bodey GP et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med. 1996; 100: 17-23.
53. Boogaerts M, Cavalli F, Cortés-Furies H et al. Granulocyte growth factors: achieving a consensus. Ann Oncol. 1995; 6: 237-44.
54. Roilides E, Pizzo PA. Modulation of host defences by cytokines. Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis. 1992; 15: 508-24.
55. Klein HG, Strauss RG, Schiffer CA. Granulocyte transfusion therapy. Sem Hematol. 1996; 33: 359-68.
56. Dale DC, Liles WC, Price TH. Renewed interest in granulocyte transfusion therapy. Br J Haematol. 1997; 98: 497-501.
57. Bensinger WI, Price TH, Dale DC et al. The effect of daily recombinant granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993; 81: 1883-8.
58. Dignani MC, Anaissie EJ, Hester JP et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997; 11: 1621-30.